An expert panel convened by the Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer’s disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias. Their guidance was published in the May 18, 2021 issue of Neurology, the medical journal of the American Academy of Neurology.
These efficiencies in clinical trials can help to achieve proof of concept more rapidly and at lower costs. The estimated cost of developing an Alzheimer’s drug…
